Molecular Targeted Therapy for Pancreatic Cancer: the End of the Beginning?
11:40 - 12:00, Room 104 (104講堂)
Molecular targeted therapy for pancreatic cancer: the end of the beginning?
Development of molecular targeted therapy for pancreatic adenocarcinoma used to be difficult because of the marked molecular heterogeneity and the lack of ‘druggable’ driver mutations in the tumors. Inhibitors of poly-(ADP-ribose) polymerase (PARP) have demonstrated efficacy of prolonging progression-free survival or overall survival as maintenance therapy in many cancer types, and the efficacy was more prominent in tumors harboring germline BRCA mutations or other homologous recombination defects.
In this presentation the pivotal trials of PARP inhibitors in pancreatic adenocarcinoma and other cancers will be summarized. Opportunities for PARP inhibitors in pancreatic adenocarcinoma, including development of predictive biomarkers and design of combination regimens, will be discussed.